Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Di Costanzo, Giovan Giuseppe ^a   Tortora, Raffaella ^a   De Luca, Massimo ^a   Galeota Lanza, Alfonso ^a   Lampasi, Filippo ^a   Tartaglione, Maria Teresa ^a   Picciotto, Francesco Paolo ^a   Imparato, Michele ^a   Mattera, Silvana ^a   Cordone, Gabriella ^a   Ascione, Antonio ^a  

^a CARDARELLI HOSPITAL   (Italy)

Author keywords

Effectiveness; Hepatocellular carcinoma; Liver cirrhosis; Safety; Sorafenib

Indexed keywords

SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; NICOTINAMIDE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASCITES; BRAIN DISEASE; CANCER GROWTH; CHILD PUGH SCORE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; JAUNDICE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; TREATMENT OUTCOME; AGE; KAPLAN MEIER METHOD; LIVER TUMOR; MIDDLE AGED; MORTALITY; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS;

MLCS; MLOWN;

EID: 84880617574     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0446-y     Document Type: Article

References (32)

1. GLOBOCAN Cancer incidence and mortality worldwide. International Agency for Research on Cancer, World Health Organization, 2010. Available at http://globocan.iarc.fr (2008). Accessed 3 June 2011.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-76.
3. Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53:744-9.
4. Stroffolini T, Trevisani F, Pinzello G, Brunello F, Tommasini MA, Iavarone M, et al. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Dig Liver Dis. 2011;43:875-80.
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;24(359):378-90.
7. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-109.
8. Liu L, Cao Y, Chen C, McNabola A, Wilkie D, Wilhelm S, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66:11851-8.
9. Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst. 2008;100:1454-63.
10. Bukowski RM, Stadler WM, McDermott DF, Figlin A, Knox JJ, Gabrail N, et al. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology. 2010;78:340-7.
11. Pili R, Guo Y, Chang J, Nakanishi H, Martin GR, Passaniti A. Altered angiogenesis under lying age-dependent changes in tumor growth. J Natl Cancer Inst. 1994;86:1303-14.
12. Kaptzan T, Skutelsky E, Itzhaki O, et al. Efficacy of anti-angiogenic treatment of tumors in old versus young mice. Mech Ageing Dev. 2006;127:398-409.
13. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol. 2001;35:421-30.
14. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-38.
15. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-81.
16. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
17. Balducci L. Geriatric oncology: challenge for the new century. Eur J Cancer. 2000;36:1741-54.
18. Yancik R, Wesley MN, Ries LA, Havlik RJ, Long S, Edwards BK, Yates JW. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82:2123-34.
19. Sastre J, Marcuello E, Masutti B, et al. Irinotecan in combination with fluorouracilin a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish cooperative group for the treatment of digestive tumors study. J Clin Oncol. 2005;23:3545-51.
20. Doherty JG, Rufer A, Bartholomew P, Beaumont DM. The presentation, treatment and outcome of renal cell carcinoma in old age. Age Ageing. 1999;28:359-62.
21. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5:224-37.
22. Kyriakou F, Kountourakis P, Papamichael D. Targeted agents: review of toxicity in the elderly metastatic colorectal cancer patients. Target Oncol. 2011;6:245-51.
23. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res. 2007;37(Suppl 2):S88-94.
24. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB, editors. Cancer incidence in five continents. Volume VIII. IARC Scientific Publications No. 155. Lyon, France: International Agency for Research on Cancer; International Association of Cancer Registries. 2002.
25. White LA, Menzin J, Korn JR, Friedman M, Lang K, Ray S. Medical care costs and survival associated with hepatocellular carcinoma among the elderly. Clin Gastroenterol Hepatol. 2012;10:547-54.
26. Mirici-Cappa F, Gramenzi A, Santi V, Zambruni A, Di Micoli A, Frigerio M, et al. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut. 2010;59:387-96.
27. Langer CJ. Clinical evidence on the undertreatment of older and poor performance patients who have advanced non-small-cell lung cancer: is there a role for targeted therapy in these cohorts? Clin Lung Cancer. 2011;12:272-9.
28. Larochelle P, Kollmannsberger C, Feldman RD, Schiffrin EL, Poirier L, Patenaude F, Ruether D, Myers M, Bjarnason G. Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents. Curr Oncol. 2012;19:202-8.
29. Imarisio I, Paglino C, Ganini C, Magnani L, Caccialanza R, Porta C. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. Future Oncol. 2012;8:1051-7.
30. Wong H, Tang YF, Yao TJ, Chiu J, Leung R, Chan P, et al. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma. Oncologist. 2011;16:1721-8.
31. Morimoto M, Numata K, Kondo M, Hidaka H, Takada J, Shibuya A, et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res. 2011;41:296-302.
32. Bellmunt J, Négrier S, Escudier B, Awada A. SIOG Taskforce. The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol. 2009;69:64-72.